Navigation Links
Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
Date:11/4/2008

ROCKVILLE, Md., Nov. 4 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2008 third quarter financial results in a press release to be issued after 8:00 a.m. Eastern Time on November 10, 2008. The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. Eastern Time on November 10, 2008. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the financial results overview. The dial-in number for the conference call is USA and Canada (866) 793-1308 International: (703) 639-1310.

A live audio webcast of the conference call will be available at http://www.novavax.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 90 days after the webcast and a replay of the conference call will also be available by telephone beginning 1pm EST. November 10, 2008 through midnight November 13, 2008. To access the replay, dial (888) 266-2081 and enter pass code 1290008.

About Novavax, Inc.

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
2. Novavax CEO to Present at BIO Investor Forum 2008
3. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
4. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
5. Novavax Announces Closing of $18 Million Registered Direct Offering
6. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
7. Novavax to Join Russell 3000 Index
8. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
11. Novavax Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... RESEARCH TRIANGLE PARK, N.C. , April ... UTHR ) today announced that its Board of ... of the company,s common stock. This program will became ... 2017. Purchases may be made in the open market, ... time to time as determined by United Therapeutics, management ...
(Date:4/27/2017)... ... , ... Mitotech S.A, a Luxembourg based clinical stage biotechnology company, announced positive ... a rare devastating genetic disease that leads to a sudden and rapid loss of ... patients carrying 11778, 14484 and 3460 mutations and having experienced the onset of symptoms ...
(Date:4/27/2017)... ... April 27, 2017 , ... During the ... review how testing for 1,25-Dihydroxyvitamin D can enhance clinical practice. Participants will learn ... 1,25 dihydroxyvitamin D. , Dr. Gregory Plotnikoff, senior consultant with Minnesota Personalized Medicine, ...
(Date:4/27/2017)... USA (PRWEB) , ... April 27, 2017 , ... ... optics and photonics , joined other scientists, researchers, engineers, and industry professionals in ... to strengthen America's ability to compete in the world photonics industry. , This ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
Breaking Biology News(10 mins):